All In Biotech

Drug Trial Radar · NCT03673501

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

453

Actual

Start

Feb 8, 2019

Primary completion

Sep 1, 2021

Study completion Dec 2027

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Sep 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).

Conditions

  • Gastrointestinal Stromal Tumors

Interventions

  • RipretinibDrug

    Oral KIT/PDGFRA kinase inhibitor

  • SunitinibDrug

    Oral receptor tyrosine kinase (RTK) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) PopulationTime frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
  2. Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) PopulationTime frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)

Locations

121 sites in 22 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • University of California San Diego Medical Center

    La Jolla, California

  • UCLA Hematology Oncology Center - Main Site

    Los Angeles, California

  • Stanford Medicine

    Stanford, California

  • University of Colorado Hospital - Anschutz Cancer Pavillion

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Smilow Cancer Hospital at Yale

    New Haven, Connecticut

  • Washington Cancer Institute at MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Orlando Health UF Health Cancer Center

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Georgia Cancer Specialists

    Sandy Springs, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • IU Simon Cancer Center

    Indianapolis, Indiana

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Norton Cancer Institute, Audubon Hospital Campus

    Louisville, Kentucky

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota Medical Center-Fairview

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • Rutgers Cancer Institute

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • The Monter Cancer Center

    Lake Success, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center-Montefiore Medical Park

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • University of Toledo

    Toledo, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University Center for Health and Healing

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.